Efficacy and safety of sofpironium in treatment of primary hyperhidrosis: a systematic review
Background Primary axillary hyperhidrosis has limited noninvasive and effective treatment, and we present the use of sofpironium bromide as a promising treatment option. We aimed to assess the efficacy and safety of sofpironium in patients with primary hyperhidrosis.Methods We systematically searche...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2024.2441258 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846125919177015296 |
|---|---|
| author | Ramez M. Odat Abdullah Yousef Aldalati Bara M. Hammadeh Ayham Mohammad Hussein Muhammad Idrees Hamza Marzouk Sakhr Alshwayyat Hamdah Hanifa |
| author_facet | Ramez M. Odat Abdullah Yousef Aldalati Bara M. Hammadeh Ayham Mohammad Hussein Muhammad Idrees Hamza Marzouk Sakhr Alshwayyat Hamdah Hanifa |
| author_sort | Ramez M. Odat |
| collection | DOAJ |
| description | Background Primary axillary hyperhidrosis has limited noninvasive and effective treatment, and we present the use of sofpironium bromide as a promising treatment option. We aimed to assess the efficacy and safety of sofpironium in patients with primary hyperhidrosis.Methods We systematically searched the databases for Studies that assessed sofpironium bromide in patients with primary axillary hyperhidrosis. Methodological quality was determined using the Cochrane Risk of Bias Assessment tool and Newcastle-Ottowa scale.Results Five studies were included (752 patients). They used 5% sofpironium, except for one study that used 5%, 10%, and 15% sofpironium. Studies have shown a significant difference in the incidence of patients with an HDSS score of 1 or 2 ranging from 53.9% to 86.7% and reported a greater reduction in the mean change in the DLQI score in the sofpironium group. They also noted a more significant reduction in the total gravimetric weight of sweat in the sofpironium group. A 1.5 point or greater improvement in HDSM-Ax score ranged from 48.2% to 69.1%. Serious adverse events were not observed in the intervention group.Conclusion Sofpironium gel provides notable improvements in symptom severity, sweat reduction, and quality of life, with mostly mild localized adverse events.Hyperhidrosis is relatively common, affecting 4.8% of the US population and negatively affects physical, social, and psychological well-being.Sofpironium bromide is recently approved by the FDA for the treatment of primary axillary hyperhidrosisSofpironium bromide showed promising results in terms of safety and efficacy for treating hyperhidrosisWe systematically assessed the use of sofpironium gel reported in five studies (752 patients)Sofpironium gel provides notable improvements in symptom severity, sweat reduction and quality of life, with mostly mild localized adverse events. |
| format | Article |
| id | doaj-art-6d18cb4a00d6425c928190cc7d871a83 |
| institution | Kabale University |
| issn | 0954-6634 1471-1753 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj-art-6d18cb4a00d6425c928190cc7d871a832024-12-13T09:15:32ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532025-12-0136110.1080/09546634.2024.2441258Efficacy and safety of sofpironium in treatment of primary hyperhidrosis: a systematic reviewRamez M. Odat0Abdullah Yousef Aldalati1Bara M. Hammadeh2Ayham Mohammad Hussein3Muhammad Idrees4Hamza Marzouk5Sakhr Alshwayyat6Hamdah Hanifa7Faculty of Medicine, Jordan University of Science and Technology, Irbid, JordanFaculty of Medicine, Jordan University of Science and Technology, Irbid, JordanFaculty of Medicine, Al-Balqa’ Applied University, Salt, JordanFaculty of Medicine, Al-Balqa’ Applied University, Salt, JordanFaculty of Medicine, Lahore General hospital Lahore, Punjab, PakistanFaculty of Medicine, Jordan University of Science and Technology, Irbid, JordanResearch Center, King Hussein Cancer Center, Amman, JordanFaculty of Medicine, University of Kalamoon, Al_Nabk, SyriaBackground Primary axillary hyperhidrosis has limited noninvasive and effective treatment, and we present the use of sofpironium bromide as a promising treatment option. We aimed to assess the efficacy and safety of sofpironium in patients with primary hyperhidrosis.Methods We systematically searched the databases for Studies that assessed sofpironium bromide in patients with primary axillary hyperhidrosis. Methodological quality was determined using the Cochrane Risk of Bias Assessment tool and Newcastle-Ottowa scale.Results Five studies were included (752 patients). They used 5% sofpironium, except for one study that used 5%, 10%, and 15% sofpironium. Studies have shown a significant difference in the incidence of patients with an HDSS score of 1 or 2 ranging from 53.9% to 86.7% and reported a greater reduction in the mean change in the DLQI score in the sofpironium group. They also noted a more significant reduction in the total gravimetric weight of sweat in the sofpironium group. A 1.5 point or greater improvement in HDSM-Ax score ranged from 48.2% to 69.1%. Serious adverse events were not observed in the intervention group.Conclusion Sofpironium gel provides notable improvements in symptom severity, sweat reduction, and quality of life, with mostly mild localized adverse events.Hyperhidrosis is relatively common, affecting 4.8% of the US population and negatively affects physical, social, and psychological well-being.Sofpironium bromide is recently approved by the FDA for the treatment of primary axillary hyperhidrosisSofpironium bromide showed promising results in terms of safety and efficacy for treating hyperhidrosisWe systematically assessed the use of sofpironium gel reported in five studies (752 patients)Sofpironium gel provides notable improvements in symptom severity, sweat reduction and quality of life, with mostly mild localized adverse events.https://www.tandfonline.com/doi/10.1080/09546634.2024.2441258Sofpironiumprimary hyperhidrosissystematic review |
| spellingShingle | Ramez M. Odat Abdullah Yousef Aldalati Bara M. Hammadeh Ayham Mohammad Hussein Muhammad Idrees Hamza Marzouk Sakhr Alshwayyat Hamdah Hanifa Efficacy and safety of sofpironium in treatment of primary hyperhidrosis: a systematic review Journal of Dermatological Treatment Sofpironium primary hyperhidrosis systematic review |
| title | Efficacy and safety of sofpironium in treatment of primary hyperhidrosis: a systematic review |
| title_full | Efficacy and safety of sofpironium in treatment of primary hyperhidrosis: a systematic review |
| title_fullStr | Efficacy and safety of sofpironium in treatment of primary hyperhidrosis: a systematic review |
| title_full_unstemmed | Efficacy and safety of sofpironium in treatment of primary hyperhidrosis: a systematic review |
| title_short | Efficacy and safety of sofpironium in treatment of primary hyperhidrosis: a systematic review |
| title_sort | efficacy and safety of sofpironium in treatment of primary hyperhidrosis a systematic review |
| topic | Sofpironium primary hyperhidrosis systematic review |
| url | https://www.tandfonline.com/doi/10.1080/09546634.2024.2441258 |
| work_keys_str_mv | AT ramezmodat efficacyandsafetyofsofpironiumintreatmentofprimaryhyperhidrosisasystematicreview AT abdullahyousefaldalati efficacyandsafetyofsofpironiumintreatmentofprimaryhyperhidrosisasystematicreview AT baramhammadeh efficacyandsafetyofsofpironiumintreatmentofprimaryhyperhidrosisasystematicreview AT ayhammohammadhussein efficacyandsafetyofsofpironiumintreatmentofprimaryhyperhidrosisasystematicreview AT muhammadidrees efficacyandsafetyofsofpironiumintreatmentofprimaryhyperhidrosisasystematicreview AT hamzamarzouk efficacyandsafetyofsofpironiumintreatmentofprimaryhyperhidrosisasystematicreview AT sakhralshwayyat efficacyandsafetyofsofpironiumintreatmentofprimaryhyperhidrosisasystematicreview AT hamdahhanifa efficacyandsafetyofsofpironiumintreatmentofprimaryhyperhidrosisasystematicreview |